Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Fortis Hospitals Mumbai, shared on LinkedIn:
“What’s new data to be presented at WCLC 2026.
Check the infographic below.
What’s New at WCLC 2026 Key
Late-Breaking Lung Cancer Abstracts
1. MAVERICK (SWOG S1827):
MRI Surveillance + PCI in SCLC
- Population: MRi-negative extensive-stage SCLC after initial therapy
- Design: Randomized phase III – MRI surveillance vs MRI + PCI
2. ARTEMIS-008:
Risvutatug Rezetecan (B7-H3 ADC) vs Topotecan in Relapsed SCLC
- Population: Relapsed SCLC (~460 pts)
- Design: Randomized phase III
3. REZILIENT 3:
Zipalertinib + Chemotherapy in 1L EGFR Exon 20 Insertion NSCLC
- Population: EGFR COFR exon 20 insertion NSCLC (untreated)
- Design: Zipalertinib and platinum/pemetrexed -> zipalertinib vs platinum/pemetrexed
4. PAPILLON – Overall Survival:
Amivantamab + Chemotherapy in EGFR Exon 20 Insertion NSCLC
- Population: EGFR exon 70 insertion NSCLC (1L)
- Design: Amivantamab + chemo vs chemotherapy
5. ADAURA – 8-Year OS Update:
Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
- Population: Resected EGFR-mutated stage IB-IIIA NSCLC
- Design: Osimertinib vs placebo (3 years)
6. Zidesamtinib (ARROS-1):
In TKI-Naive ROS1+ NSCLC
- Population: Advanced ROS1+ NSCLC (TKI-naive)
- Design: Single-arm phase I/II
7. EVOKE-03 (KEYNOTE D46):
Sacituzumab Govitecan + Pembrolizumab vs Pembrolizumab in PD-L1 TPS =50% NSCLC
- Population: PO-L1 TPS =50%, untreated metastatic NSCLC
- Design: Randomized phase III
WCLC 2026 will be held 12-15 September 2026 in Seoul, Korea. Detailed results to be presented at the meeting.”
Other articles featuring Amol Akhade on OncoDaily.